ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SNG Synairgen Plc

4.675
0.00 (0.00%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.675 4.36 4.99 - 60,335 08:00:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.53 9.41M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 4.68p. Over the last year, Synairgen shares have traded in a share price range of 3.65p to 10.62p.

Synairgen currently has 201,374,975 shares in issue. The market capitalisation of Synairgen is £9.41 million. Synairgen has a price to earnings ratio (PE ratio) of -0.53.

Synairgen Share Discussion Threads

Showing 31551 to 31574 of 99175 messages
Chat Pages: Latest  1267  1266  1265  1264  1263  1262  1261  1260  1259  1258  1257  1256  Older
DateSubjectAuthorDiscuss
01/10/2020
22:30
You all have coins!
nobbygnome
01/10/2020
22:23
Sorry for the typo...... NobbyThanks
richafling
01/10/2020
22:22
BobbyI would like to join the Guild boardI am a Long term shareholder starting from a few weeks ago now and very interested to understand the views and opinions about the future of Interferon and how SNG might drive this therapy to the massesMany thanks
richafling
01/10/2020
22:04
From ducati2 on lse-https://www.medscape.com/viewarticle/933621#vp_2Medicine and the Machine from 8.22 minsTopol: A paper just came out in Nature Reviews Immunology that reviewed four small ongoing trials and that multicenter study from China. All of them look quite promising. If you were to predict the future, do you envision that we all could have an inhaler with an IFN that we would take at first diagnosis or exposure? Do you think that's a possibility?Iwasaki: As long as we can give the right dose without toxicity, that may be the future, especially in a preventive setting. For example, if your family member was diagnosed with a viral infection, you could potentially treat the rest of the family members with prophylactic IFN, and healthcare workers or people who are exposed to high-dose virus on a daily basis. That's what happened in China; they gave an inhaled IFN to healthcare workers and none of them were infected. So this may be a good thing to do in the future.
tickboo
Chat Pages: Latest  1267  1266  1265  1264  1263  1262  1261  1260  1259  1258  1257  1256  Older

Your Recent History

Delayed Upgrade Clock